Polaryx Therapeutics, Inc. Common Stock

NASDAQ:PLYX

Biotechnology

Healthcare
$1.61 -0.87%

-$0.02 today

Market cap
$80.25M
Beta
0.00
P/E (TTM)
-16.7
EPS (TTM)
-$0.14
52W Low $2.01High $48.91

Volume 0.02M

Average 0.34M

Income Statement

Follow revenue through to earnings.

Revenue

$0.00

FY 2025 · Annual

Operating Income

-$7.82M

FY 2025 · Annual

Net Income

-$8.98M

FY 2025 · Annual

Income Statement

USD
Metric
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue000
Cost of Revenue000
Gross Profit000
Gross Margin———
Research & Development2.77M2.81M6.27M
Selling, General & Admin1.01M1.54M1.56M
Operating Expenses3.78M4.35M7.82M
Depreciation & Amortization000
EBITDA(3.78M)(30.36M)(8.99M)
EBITDA Margin———
Operating Income(3.78M)(4.35M)(7.82M)
Operating Margin———
Interest Income000
Interest Expense000
Other Income / Expenses2K(26M)(1.16M)
Income Before Tax(3.78M)(30.36M)(8.99M)
Pre-Tax Margin———
Income Tax Expense000
Net Income(3.78M)(30.36M)(8.99M)
Net Margin———
EPS (Basic)(0.02)(0.16)(0.19)
EPS (Diluted)(0.02)(0.16)(0.19)
Weighted Avg Shares189.37M189.37M47.34M
Weighted Avg Shares (Diluted)189.37M189.37M47.34M

PLYX Earnings Waterfall · TTM

NASDAQ:PLYX · Revenue to Net Income

Key Ratios

EPS$-0.10
Gross Margin0.0%
Net Margin0.0%
P/E Ratio-778.7
P/S Ratio0.0

Analysis

$0 of revenue converted into -$6.5M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-0.10, tying the income statement back to per-share earnings.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
10-QQuarterly reportNov 12, 2026
8-KCurrent reportSep 14, 2026
8-KCurrent reportSep 1, 2026
10-QQuarterly reportAug 13, 2026
ARSARS filingJul 28, 2026

How much revenue does PLYX generate?

Polaryx Therapeutics, Inc. Common Stock (PLYX) reported $0.00 of revenue in fiscal 2025.

Is PLYX profitable?

Polaryx Therapeutics, Inc. Common Stock (PLYX) reported -$8.98M of net income.